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Abstract: Gestational diabetes mellitus (GDM) is commonly defined as glucose intolerance 
first recognized during pregnancy. Diagnostic criteria for GDM have changed over the decades, 
and several definitions are currently used; recent recommendations may increase the prevalence 
of GDM to as high as one of five pregnancies. Perinatal complications associated with GDM 
include hypertensive disorders, preterm delivery, shoulder dystocia, stillbirths, clinical neonatal 
hypoglycemia, hyperbilirubinemia, and cesarean deliveries. Postpartum complications include 
obesity and impaired glucose tolerance in the offspring and diabetes and cardiovascular disease 
in the mothers. Management strategies increasingly emphasize optimal management of fetal 
growth and weight. Monitoring of glucose, fetal stress, and fetal weight through ultrasound 
combined with maternal weight management, medical nutritional therapy, physical activity, 
and pharmacotherapy can decrease comorbidities associated with GDM. Consensus is lacking 
on ideal glucose targets, degree of caloric restriction and content, algorithms for pharmaco-
therapy, and in particular, the use of oral medications and insulin analogs in lieu of human 
insulin. Postpartum glucose screening and initiation of healthy lifestyle behaviors, including 
exercise, adequate fruit and vegetable intake, breastfeeding, and contraception, are encouraged 
to decrease rates of future glucose intolerance in mothers and offspring.
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Introduction
Gestational diabetes mellitus (GDM) is commonly defined as glucose intolerance first 
recognized during pregnancy.1 The prevalence of GDM is increasing, fueled by advanc-
ing maternal age, racial/ethnic shifts in childbearing, and obesity.2 Several studies, 
including the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Study,3 the 
Australian Carbohydrate Intolerance in Pregnancy (ACHOIS) randomized trial,4 and 
the Metformin in Gestational Diabetes (MiG) randomized trial,5 have helped clarify 
several diagnostic and treatment issues, while raising additional questions. In this 
article, the current thinking regarding screening and diagnosis, complications, and 
management options for GDM are reviewed.
Diagnosis of GDM
Diagnostic criteria for GDM have changed over the decades, and several definitions 
are currently used. The reasons for this variation are rich and complicated,   reflecting 
declines in perinatal mortality, advances in assay technology, evolving access to care, 
epidemiology, and local cultural practices. For an excellent summary of the early 
  history of GDM, the reader is referred to Hadden’s essay6 outlining screening guidelines International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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and diagnostic cutpoints from more recent times, which are 
illustrated in Table 1.
The American Diabetes Association (ADA) recommends 
screening for GDM at the time of pregnancy diagnosis if 
any of the following conditions are present: severe obesity, 
prior history of GDM or delivery of an infant that is large 
for gestational age (LGA), glycosuria, polycystic ovarian 
syndrome, or family history of type 2 diabetes.7 If these 
risk factors are not present, women are to undergo diabetes 
screening at 24–28 weeks’ gestation if any of the following 
conditions are present: age $25 years, overweight before 
pregnancy, nonwhite race/ethnicity, family history of dia-
betes, history of abnormal glucose tolerance, or history of 
poor obstetric outcome. The American College of Obstetrics 
and Gynecology (ACOG) has similar recommendations.8 
In contrast, the World Health Organization recommends 
universal screening of all women for GDM at 24–28 weeks’ 
gestation.9
To resolve the questions regarding optimal diagnostic 
  cutpoints, the National Institutes of Health and other health 
care organizations sponsored HAPO, an international 
  prospective cohort study.3 Approximately 25,000 pregnant 
women   underwent a 75 g oral glucose tolerance test (OGTT) 
and careful assessment of perinatal outcome measures, with 
blinding of caregivers and subjects. Women with particularly 
elevated glucose levels were unblinded and treated. The final 
study cohort includes only women with glucose values for 
which risk of adverse outcomes was uncertain.
The study found that the risk of adverse pregnancy 
  outcomes increased continuously with glucose levels.3 
Primary outcomes included birthweight above the 90th 
percentile for gestational age, cesarean delivery, clinical 
neonatal   hypoglycemia, and cord serum C-peptide values 
above the 90th percentile. Secondary outcomes included 
preterm delivery (less than 37 weeks’ gestation), sum of skin-
folds above the 90th percentile for gestational age, percent 
body fat greater than the 90th percentile for gestational age, 
admission to neonatal intensive care, hyperbilirubinemia, 
pre-eclampsia, and birthweight under the 10th percentile 
for gestational age.
Table 1 Screening guidelines from the American Diabetes Association (ADA),7 the American College of Obstetrics and Gynecology 
(ACOG),8  the  World  Health  Organization  (WHO),9  and  the  Hyperglycemia  and  Adverse  Pregnancy  Outcomes  Study  Group   
(HAPO)10
ADA ACOG WHO HAPO
Strategy 1
During a 100 g glucose challenge,  
exceeds 2 of the following:  
fasting $95 mg/dL (5.3 mM/L)
1-hour $180 mg/dL (10 mM/L)
2-hour $155 mg/dL (8.6 mM/L)
3-hour $140 mg/dL (7.8 mM/L)
OR
Strategy 2
After a 50 g glucose challenge,  
exceeds 130–140 mg/dL  
(7.2–7.8 mM/L)
AND
then fails Strategy 1
OR
Strategy 3
During a 75 g challenge,  
exceeds 1 of the following:  
fasting $95 mg/dL (5.3 mM/L)
1-hour glucose $155 mg/dL (8.6 mM/L)
2-hour glucose $140 mg/dL (7.8 mM/L)
Strategy 1
After a 50 g glucose challenge,  
exceeds130–140 mg/dL  
(7.2– 7.8 mM/L)
AND
During a 100 g glucose challenge,  
exceeds 2 of the following: 
fasting $ 95 mg/dL (5.3 mM/L)
1-hour $ 180 mg/dL (10 mM/L)
2-hour $ 155 mg/dL (8.6 mM/L)
3-hour $ 140 mg/dL (7.8 mM/L)
OR
Strategy 2
After a 50 g glucose challenge,  
exceeds 130–140 mg/dL  
(7.2– 7.8 mM/L)
AND
During a 100 g glucose  
challenge,  
exceeds 2 of the following:  
fasting $105 mg/dL (5.8 mM/L)
1-hour $190 mg/dL (10.6 mM/L)
2-hour $165 mg/dL (9.2 mM/L)
3-hour $145 mg/dL (8.0 mM/L)
Strategy 1
During a 75 g challenge,  
exceeds 1 of the following:  
 
fasting $126 mg/dL (7.0 mM/L)
2-hour glucose $140 mg/dL 
(7.8 mM/L)
Strategy 1
During a 75 g glucose challenge,  
exceeds 1 of the following:  
 
fasting $92 mg/dL (5.1 mM/L)
1-hour $180 mg/dL (10 mM/L)
2-hour $153 mg/dL (8.5 mM/L)International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Subsequently, the International Association of Diabetes 
and Pregnancy Study Groups (IADSPG) consensus panel 
members defined glucose cutpoints for GDM as those 
associated with odds ratios (OR) of 1.75 for perinatal risks 
compared with mean glucose values.10 These cutpoints are 
illustrated in Table 1, along with guidelines from several 
other organizations. At the time of writing, these other 
health care organizations are considering an endorsement 
of these recommendations. One of the implications is that 
many more women will be diagnosed with GDM, and the 
subsequent effects regarding their care and demands on health 
care resources are unknown. Lawrence et al have estimated 
that approximately 20% of pregnant women in the Kaiser 
Permanente Southern California health care system would be 
diagnosed with GDM if HAPO criteria were applied.11
Risks of GDM-related perinatal 
complications
In a review from 1991,12 O’Sullivan observed, “Although 
the variability in diabetes incidence rates is wide, there is 
broad general agreement on the predictive nature of gesta-
tional blood glucose levels”. This statement still holds for 
both fetal and maternal complications. In recent years, there 
has been increased attention paid to the substantial overlap 
in complications of GDM and obesity during pregnancy.13 
This attention has been focused by changes in the recom-
mendations for weight changes during pregnancy,14 along 
with the steady rise in obesity in industrialized countries. 
Complications associated with GDM may be, at least in 
part, explained by the increased body mass index (BMI) 
of GDM women. While there are women who do not meet 
BMI criteria for obesity but are nevertheless “metabolically 
obese”, the overwhelming majority of women with GDM are 
overweight or obese.15 In the following paragraphs, the most 
common morbidities of GDM are reviewed. When possible, 
a distinction is made between complications associated with 
obesity as compared with those associated with abnormal 
glucose levels.
Hypertensive disorders
Women with GDM have an increased incidence of hyper-
tensive disorders during pregnancy, including gestational 
hypertension, chronic hypertension, pre-eclampsia, and 
eclampsia. The prevalence of these disorders varies slightly 
across studies. In HAPO, which included women with and 
without GDM, approximately 2.5% of women had chronic 
hypertension (582 of 23,316 women), 5.9% had gestational 
hypertension, and 4.8% had pre-eclampsia.16 Similarly in the 
randomized MiG trial, which only included GDM women, 
about 5.0% of women had gestational hypertension and 6.3% 
had pre-eclampsia.5 However, the randomized ACHOIS trial 
reported that 15% of its GDM population had pre-eclampsia, 
notably higher than other prospective studies.4
Currently, it is not known whether the overlap in GDM 
and hypertensive disorders reflects a common causal path-
way. Both GDM and hypertensive disorders are associated 
with factors such as insulin resistance, inflammation, and 
maternal fat deposition patterns.17 In HAPO,16 increased 
glucose levels on the index OGTT were associated with a 
greater risk of pre-eclampsia, even after adjustment for fac-
tors including maternal age, BMI, height, smoking status, 
alcohol use, family history of diabetes, gestational age at 
the time of the index OGTT, infant gender, parity, and cord 
plasma glucose. Of note, elevations in all glucose levels, ie, 
fasting glucose (adjusted OR, 1.21; 95% confidence interval 
[CI]: 1.13–1.29), 1-hour glucose (adjusted OR, 1.28; 95% 
CI: 1.20–1.37), and 2-hour glucose (adjusted OR, 1.28; 
95% CI: 1.20–1.37) were associated with greater odds of 
pre-eclampsia.
Although the causality of GDM and hypertensive disorders 
is not clear, pregnancies affected by both GDM and chronic 
hypertension have higher rates of induction of labor compared 
with pregnancies affected by GDM alone (36.7% versus 6.6%).18 
Other perinatal outcomes, such as the incidence of small-for-
gestational-age or LGA deliveries, do not seem to be exacerbated 
by the presence of both GDM and hypertension.18
Preterm delivery
Preterm delivery is usually defined as delivery ,37 weeks’ 
gestation.19 While acknowledged as a risk of GDM, spon-
taneous preterm delivery is less common compared with 
other adverse outcomes. In the HAPO study, approximately 
1608 of the 23,316 participants (6.9%) experienced preterm 
delivery (both induced and spontaneous), compared with 
9.6% of infants who were LGA and 8.0% of infants who 
underwent intensive neonatal care admission.3 Moreover, of 
the primary and secondary outcomes examined in HAPO, 
preterm delivery had minimal association with fasting 
glucose levels after consideration of multiple factors noted 
earlier, as well as maternal blood pressure (adjusted OR, 
1.05; 95% CI: 0.99–1.11). Associations with the 1-hour 
glucose level (adjusted OR, 1.18; 95% CI: 1.12–1.25) 
and the 2-hour glucose level (adjusted OR, 1.16; 95% CI: 
1.10–1.23) were statistically significant, but relatively weak 
compared with the associations between glucose levels and 
other outcomes.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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The association between GDM and preterm delivery may 
be partially explained by the coexistence of other conditions 
with GDM that may lead to indicated or induced preterm 
delivery. Such conditions include pre-eclampsia and hyperten-
sive-associated conditions, such as intrauterine growth restric-
tion and placental abruption. However, spontaneous preterm 
birth, or birth in the absence of conditions prompting medical 
intervention, accounts for approximately three-quarters of 
preterm births and is not associated with GDM.3,19
Shoulder dystocia
Shoulder dystocia is usually defined as the need for additional 
maneuvers to deliver the shoulders if gentle traction on the fetal 
head does not suffice.20 In HAPO, shoulder dystocia was one 
of the least common outcomes, with only 1.3% of the women 
affected.3 While shoulder dystocia increases risk of birth 
trauma to the infant, these injuries are fortunately not the rule; 
brachial plexus palsy, which often resolves in early infancy,21 
occurs in only 4%–13% of shoulder dystocia deliveries.22
The risk of shoulder dystocia increases with obesity and 
additionally with GDM. Even after consideration of maternal 
weight, women with glucose intolerance during pregnancy 
have slightly increased odds of dystocia.3,23 The increased 
risk conferred by GDM is thought to be related to other 
anthropometric abnormalities in GDM infants, particularly 
truncal obesity and larger shoulder diameter, as well as 
heavier maternal weight. In HAPO, shoulder dystocia was 
associated with increases in fasting glucose (adjusted OR, 
1.18; 95% CI: 1.04–1.33), 1-hour glucose (adjusted OR, 1.23; 
95% CI: 1.09–1.38), and 2-hour glucose (adjusted OR, 1.22; 
95% CI: 1.09–1.37) after adjustment for maternal BMI and 
height, among the other factors noted earlier.
Risk of stillbirth
Before the advent of treatment of GDM, untreated GDM was 
noted to increase risk of stillbirth by approximately four-
fold.24 In more recent years and in industrialized nations, 
stillbirth is an uncommon outcome, even among women 
with glucose intolerance. Reduced stillbirth rates have 
been attributed to initiation of insulin therapy combined 
with closer monitoring and subsequent induction of labor 
as necessary.8 In a study population consisting primarily 
of women with GDM, the stillbirth rate was approximately 
1.4 per 1000 births.25 Due to its rarity, it is difficult to assess 
the   relationship between stillbirth and glucose levels or 
  stillbirth and treatment in HAPO and the trials noted earlier. 
In HAPO, only 130 women (0.56%) of the 23,316 deliveries 
experienced a perinatal death, 89 of which were fetal and 41 
of which were neonatal.3 This figure was not large enough to 
assess the association with OGTT glucose levels.
Hypoglycemia in the newborn
Clinical hypoglycemia in the newborn is a complication 
of GDM, but in studies that enroll participants and thus 
probably involve closer monitoring than in general settings, 
hypoglycemia is relatively infrequent.8 In HAPO,3 clini-
cal hypoglycemia was diagnosed on the basis of treatment 
with intravenous glucose infusion or low levels of glucose, 
defined as ,30.6 mg/dL in the first 24 hours after delivery 
or  45 mg/dL glucose after the first 24 hours. By these defini-
tions, only 480 of the 23,316 women (2.1%) had infants with 
clinical hypoglycemia.
The reasons for neonatal hypoglycemia include physi-
ologic fluctuations in glucose seen in GDM women, apart 
from treatment. Maternal hyperglycemia is thought to lead to 
excess fetal glucose exposure and fetal hyperinsulinemia.26 
In turn, fetal hyperinsulinemia is thought to lead to hyper-
plasia of fat tissue, skeletal muscle, and subsequent neonatal 
hypoglycemia.26 In HAPO, after adjustment for other factors 
mentioned earlier, infant hypoglycemia was associated with 
maternal one-hour glucose (adjusted OR, 1.13; 95% CI: 
1.03–1.26) and weakly associated with maternal two-hour 
glucose (adjusted OR, 1.10; 95% CI: 1.00–1.12), although 
not significantly associated with maternal fasting glucose 
(adjusted OR, 1.08; 95% CI: 0.98–1.19) on the index OGTT.23 
Additional effects on infant metabolism are reviewed in more 
detail in the next section.
Such hypoglycemia is not necessarily worsened by the 
pharmacotherapy that often accompanies GDM diagnosis. 
In ACHOIS, the prevalence of clinical hypoglycemia was 
7% in GDM receiving intervention and 5% in GDM not 
receiving intervention, which was a nonsignificant differ-
ence.4 Similarly, in a multicenter randomized trial in the 
US,27 the prevalence of clinical neonatal hypoglycemia was 
similar in the intervention and control arms (5.3% and 6.8%, 
respectively).
Hyperbilirubinemia
Hyperbilirubinemia is more common among women with 
GDM than in women without GDM, but is still fairly 
  infrequent. In HAPO,3 hyperbilirubinemia was defined 
as treatment with phototherapy after birth, or at least 
one   laboratory report of a bilirubin level $20 mg/dL, or 
  readmission to the hospital for hyperbilirubinemia. Approxi-
mately 8.3% of women were affected. Maternal hyperglyce-
mia and the subsequent induction of fetal   hyperinsulinemia International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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and reduced oxygenation are hypothesized to lead to 
increased fetal oxygen uptake, fetal erythropoiesis, and sub-
sequent hyperbilirubinemia.28 However, other mechanisms 
may also be involved, given the common occurrence of 
hyperbilirubinemia and its relatively mild association with 
glucose levels; the association with fasting glucose was not 
significant and the associations with 1-hour glucose (adjusted 
OR, 1.11; 95% CI: 1.05–1.17) and 2-hour glucose (adjusted 
OR, 1.08; 95% CI: 1.02–1.13) were mild.
Cesarean delivery
Cesarean delivery has been successfully employed as an 
intervention used to reduce complications associated with 
GDM, particularly shoulder dystocia. However, as a major 
surgery in a gravida, it poses risks to both the fetus and the 
mother. Thus, the elevated rate of cesareans among GDM 
women can be interpreted as both an unfortunate side effect 
of diagnosis, as well as an appropriate response to the other 
morbid conditions associated with GDM, particularly shoul-
der dystocia and elevated fetal weight.
Cesarean deliveries are common among women with 
and without GDM. In HAPO, 16% of women underwent 
primary cesarean sections and 7.7% underwent repeat 
cesarean   sections.3 Elevated fasting glucose (adjusted OR, 
1.11; 95% CI: 1.06–1.15), 1-hour glucose (adjusted OR, 
1.10; 95% CI: 1.06–1.15), and 2-hour glucose (adjusted OR, 
1.08; 95% CI: 1.03–1.12) were all associated with increased 
odds of primary cesarean deliveries. This greater OR was 
after adjustment for maternal BMI and blood pressure, as 
well as practitioner knowledge of glucose levels. Most likely, 
the greater risk of cesarean is due to the other independent 
risk factors these women have for surgical intervention, 
particularly elevated fetal weight.
Whether cesarean deliveries should be routinely per-
formed in women with elevated fetal weights is controversial, 
because no randomized trials exist to address this question. 
In the Toronto Tri-Hospital Study, women with treated GDM 
had a lower rate of macrosomia than women for whom glucose 
levels were blinded, but women with identified GDM had a 
two-fold increased risk of cesarean delivery.29 These findings 
suggest that the GDM diagnosis itself, apart from fetal weight, 
was an (unnecessary) risk factor for surgery. Along similar 
lines, whether induction should be offered in anticipation of 
reducing comorbidities in glucose intolerant mothers is also 
controversial, because no randomized trials exist. A Cochrane 
database review concluded that inducing glucose intolerant 
mothers at 38 weeks’ gestation was associated with reductions 
in birthweight and did not increase risk of cesarean delivery,30 
but delay of delivery in women with well-controlled GDM 
has also not been shown to be harmful.
The operation itself is associated with several maternal 
morbidities, particularly wound infection and dehiscence, 
postpartum infection and bleeding, and deep venous throm-
bosis, as well as the need for future cesarean section with 
subsequent pregnancies.31–33 These are exacerbated by the 
presence of obesity. Data are sparse for the complications 
of cesareans among GDM women and obese women. In one 
small study, obese women had higher infection rates if they 
underwent a vertical compared with transverse skin incision 
(34.6% versus 9.4%),34 although another study did not con-
firm these findings.35 There is also no consensus regarding 
subcutaneous closure and dehiscence or use of postoperative 
heparin therapy in obese women, although stockings are 
usually recommended.13
In the infant, elective delivery in late preterm or early term 
infants has been associated with an increase in both respiratory 
distress syndrome and transient tachypnea of the newborn. 
Although women with GDM did not independently have an 
increased risk of respiratory distress syndrome or tachypnea 
of the newborn, cesarean delivery independently increased 
the risk of respiratory distress syndrome (adjusted relative 
risk, 2.21; 95% CI: 2.04–2.27). Risk increased with earlier 
gestational age.36 Accurate pregnancy dating, delaying deliv-
ery until term, and achieving euglycemia, are factors cited in 
the reduction of incidence of respiratory distress syndrome to 
less than 10% of all births.36 Partly due to the rarity of these 
conditions, routine assessment of fetal lung maturation after 
38 weeks’ gestation in GDM women is not recommended.1
Risks of GDM-related metabolic 
complications in offspring
The effects of GDM upon fetal health may still be conceptu-
alized through the framework of the Pederson hypothesis,37 
which postulated that intrauterine exposure could lead to 
permanent changes in fetal metabolism. During the GDM 
pregnancy, the fetus may be imprinted or programmed, 
  resulting in excess fetal growth, decreased insulin sensi-
tivity, and impaired insulin secretion.38 In the short term, 
elevated infant birthweight confers perinatal risks, such 
as shoulder dystocia and infant hypoglycemia.39 In the 
longer term, altered fetal metabolism may be associated 
with impaired glucose tolerance during early youth and 
adolescence.39
Typically, infant mass is represented by birthweight 
due to its ease of measurement compared with other 
indices which attempt to define specific components of International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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weight, including fat mass. The measurement of fat mass 
in infants can be more difficult, as suggested by the higher 
coefficients of variation for other anthropometric indices com-
pared with birthweight.23 However, several studies conducted 
by Catalano et al comparing infants of GDM pregnancies 
and infants of glucose tolerant pregnancies have demon-
strated that fat mass was elevated in the GDM pregnancies, 
while birthweight was not necessarily elevated.39
HAPO was able to examine the incidence of LGA infants, 
as well as more specific anthropometric measures and their 
association with index glucose levels. These other measures 
included skin-fold thickness from the flank, subscapular 
region, or triceps region, and percent body fat based on 
measurements of total body electrical conductivity and birth-
weight.23 Approximately 9.6% of babies had a birthweight 
above the 90th percentile. The associations between glucose 
levels and more specific anthropometric measures of skin 
folds and percent body fat were not noticeably stronger than 
associations between glucose levels and birthweight (fasting 
glucose adjusted OR, 1.38; 95% CI: 1.32–1.44, one-hour 
glucose adjusted OR, 1.46; 95% CI: 1.39–1.53, two-hour 
glucose adjusted OR, 1.38; 95% CI: 1.32–1.44). However, all 
measures were associated with cord insulin levels, consistent 
with the hypothesis that maternal glucose intolerance influ-
ences fetal metabolism through several pathways.
Studies regarding the association between GDM and later 
childhood metabolism conflict.40 The link between glucose 
intolerance during pregnancy and childhood weight, beyond 
birthweight, was first demonstrated in the Pima Indians41 then 
in the Northwestern Diabetes in Pregnancy Study.42 In the 
latter study, amniotic insulin was correlated with childhood 
weight. More recently, the SEARCH cohort case-control 
study found that youth with diabetes were more likely to have 
been exposed to diabetes in utero than controls.43 While the 
Framingham Offspring Study was unable to assess maternal 
exposure, it was able to examine maternal age of diabetes 
onset, a proxy for glucose intolerance during the reproduc-
tive years and therefore during pregnancy.44 Children whose 
mothers had onset of glucose intolerance when they were 
less than 50 years of age were more likely to have diabetes 
than those who did not.44
In contrast, other retrospective cohorts have not found that 
GDM was associated with childhood BMI beyond adjustment 
for infant birthweight, although in one study, information on 
weight was obtained from self-report and cohort retention 
was below 65%.45 The presence of GDM along with elevated 
birthweight may exacerbate glucose intolerance associated 
with elevated birthweight alone.46
Risks of GDM-related metabolic 
complications in mothers
The link between GDM and postpartum diabetes in the 
mother has long been recognized. O’Sullivan’s original 
OGTT cutpoints were based on risk of maternal diabetes, as 
opposed to the perinatal complications mentioned earlier.12 
Approximately 5%–10% of cases of GDM are assumed 
to be previously undetected cases of diabetes, based upon 
background prevalence of diabetes in the population.47 The 
remaining and vast majority of GDM cases are attributable to 
the metabolic stresses of pregnancy combined with impaired 
insulin secretory response.48
The reduced beta-cell reserve in GDM women can mani-
fest in the decade after delivery.49 Even among women who 
have a normal postpartum glucose tolerance test, the risk 
of future diabetes may be up to seven-fold higher than in 
women without histories of GDM.50 As many as one-third 
of women with diabetes may have been affected by prior 
GDM.51 In turn, the increased risk of diabetes is associated 
with future maternal cardiovascular disease.52,53 The greater 
risk of cardiovascular disease seems to occur primarily in 
women who develop diabetes, rather in women who remain 
glucose-tolerant.52,53
Prenatal management 
and treatment options
Once women are identified as having a GDM pregnancy, 
they are asked to engage in a management program to reduce 
the risks noted above. The value of identifying and treating 
GDM was established in the past five years with two large 
randomized trials, one conducted in the US through the 
Maternal Fetal Network54 and the other, the ACHOIS study 
conducted in Australia.4 It is assumed that such programs 
are most effectively delivered by a team of providers, spe-
cifically including nutritionists and diabetes educators, in a 
care delivery model similar to chronic diabetes education.55 
Management during pregnancy consists of monitoring of 
blood glucose and medical nutrition therapy consisting of 
caloric restriction, physical activity, and pharmacotherapy, 
if glucose goals are not met. These recommendations are 
usually accompanied by weight management, given the high 
prevalence of overweight and obesity in GDM women.15 
Management after pregnancy consists of postpartum screen-
ing for maternal diabetes, effective contraception that does 
not exacerbate underlying glucose intolerance, breastfeeding, 
and initiation or maintenance of healthy lifestyle behaviors. 
A summary of the goals for management during and after 
pregnancy are outlined in Table 2.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Recommendations for glucose and weight goals during 
and after pregnancy
Monitoring Weight
During pregnancy
Glucose level targets (whole blood): 
Fasting #95 mg/dL (5.3 mM/L) 
1-hour #130–140 mg/dL (7.8 mM/L) 
2-hour #120 mg/dL (6.7 mM/L)
If BMI , 18.5 kg/m2,  
28–40 lbs recommended, with 
1.0–1.3 lbs/week in 2nd/3rd 
trimesters
Self-monitoring of kick counts 
during the last 8–10 weeks of 
pregnancy
If BMI 18.5–24.9 kg/m2,  
25–35 lbs recommended, with 
0.8–1.0 lbs/week in 2nd/3rd 
trimesters
Fetal NST  
at 32–37 weeks, followed 
by contraction stress testing, Doppler 
evaluation of the umbilical artery, and/or 
biophysical testing  
if NST equivocal
If BMI 25–29.9 kg/m2, 
15–25 lbs recommended, with   
0.5–0.7 lbs/week in 2nd/3rd 
trimesters
Fetal ultrasound for assessment of 
congenital malformations and 
estimates of fetal weight
If BMI $ 30 kg/m2, 
11–20 lbs recommended, with 
0.4–0.6 lbs/week in 2nd/3rd 
trimesters
After pregnancy
Postpartum screening consisting of 
fasting glucose alone
BMI , 25 kg/m2
OR
2-hour 75 g OGTT
Glucose level targets (plasma): 
fasting #100 mg/dL (5.6 mM/L)
2-hour #140 mg/dL (7.8 mM/L)  
after a 75 g challenge
Abbreviations:  OGTT,  oral  glucose  tolerance  test;  BMI,  body  mass  index; 
NST, nonstress testing.
Monitoring of glucose and weight 
recommendations
Guidelines for weight gain during pregnancy have been a 
moving target over recent decades, due to the increasing rates 
of obesity, as well as glucose intolerance during pregnancy. In 
2010, the Institute of Medicine revised its guidelines for weight 
gain during pregnancy,14 and these are illustrated in Table 2. 
Weight goals are stratified by prepregnancy weight gain, as well 
as rate of weight gain in the second and third trimesters. These 
recommendations have been endorsed by the ADA.56 The ADA 
also discourages weight reduction during pregnancy in order 
to avoid ketosis. In general, ACOG recommends endorsing 
Institute of Medicine guidelines for weight,13 and ACOG has 
not specifically commented on the latest weight guidelines.
Weight targets are particularly emphasized if glucose 
goals are not met, although weight targets are also encour-
aged independently from glucose levels. Small reductions 
in weight can improve glycemic control.13 Target glucose 
levels recommended by ACOG8 and ADA7 are outlined in 
Table 2. Of note, these glucose cutpoints are higher than 
those noted in the HAPO study to pose risk of complications 
because the association between glucose and comorbidities 
is continuous.3
In order to determine whether these glucose targets are 
met, women need to engage in glucose self-monitoring or 
monitoring needs to be done by other means. While the 
ADA does not recommend a daily monitoring schedule, 
postprandial blood glucose measurements are emphasized 
over preprandial measurements.7 Urine glucose testing is not 
specifically recommended by the ADA but is a common prac-
tice. If women have elevated whole blood fasting glucose, ie, 
about 95 mg/dL (5.3 mM/L), or if the pregnancy is postdates, 
additional surveillance in the form of ultrasonography is 
often performed for detection of asymmetric abnormal fetal 
growth, particularly in the third trimester, as discussed later 
under fetal monitoring.7
Caloric intake
The cornerstone of management of the GDM pregnancy is 
medical nutrition therapy. There is broad consensus that the 
goals of such therapy are to allow appropriate weight gain 
based on the mother’s prepregnancy and prenatal weight, 
along with normoglycemia and absence of urine ketones. 
However, the degree of caloric restriction is not agreed upon. 
Short-term examination of energy restriction demonstrated 
that severe, ie, 50%, energy restriction was associated with 
ketonemia and ketonuria even as glucose and insulin levels 
declined,57 whereas more moderate energy restriction, ie, 
1600–1800 kcal/day was not associated with ketonemia.58 
Longer-term studies of energy restriction were not pow-
ered to evaluate effects on birthweight, although the rate 
of fetal growth, need for insulin, and amount of insulin 
eventually needed for some women were reduced.59 When 
obese women consume at least 25 kcal/kg/day, ketosis and 
intrauterine growth retardation do not occur.58 Therefore, the 
ADA encourages obese women (BMI $ 30 kg/m2) to reduce 
their caloric intake by 30%,7 while ACOG notes that further 
evidence is needed.8
The composition of the calories to be consumed is con-
troversial. In one study, low carbohydrate diets were associ-
ated with fewer macrosomic infants, cesarean deliveries, and 
pharmacotherapy.60 However, another study found that high 
carbohydrate diets were, unexpectedly, associated with lower 
macrosomia rates, possibly because diets rich in complex 
carbohydrates and low glycemic foods may enable greater International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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carbohydrate consumption.61 In support of this hypothesis, 
another study found that a low glycemic diet was associated 
with lower insulin use, although the study was not powered 
to determine effects on birthweight.62 In the face of this 
uncertainty, the ADA recommends the proportion of dietary 
carbohydrate be limited to about 40%–45% of total caloric 
consumption,63 while others note that carbohydrate consump-
tion can be higher if they are complex.59
Currently, no organizations recommend specific amounts 
and sources of fat consumption for women with GDM. Poly-
unsaturated fatty acids may be protective against impaired 
glucose tolerance, whereas saturated fatty acids can increase 
glucose and insulin levels in women with GDM,64 but the 
exact amounts that might be beneficial, and furthermore 
beneficial in a GDM pregnancy, are not known.
Physical activity
Up to 39% of women with GDM cannot meet glucose targets 
through diet alone.65 Physical activity may improve glucose 
tolerance by improving insulin sensitivity66 involving muscle 
glucose uptake and glycogen synthesis,67 and therefore physi-
cal activity is a logical adjunct to dietary therapy. Historically, 
this potential benefit has been outweighed by the concern that 
exercise could theoretically lead to an increase in secretion 
of insulin, free fatty acids, and ketones, with a concomitant 
decrease in glucose levels.7,68 However, several small studies 
that demonstrate the safety of exercise during pregnancy and 
the association with either better cardiorespiratory fitness or 
mean glucose values.7,68–70
General guidelines encourage at least 30 minutes of physi-
cal activity on several days a week, or the equivalent.7,68 More 
tailored activity based on women’s fitness and prepregnancy 
physical activity levels might be more effective at addressing 
glucose and weight targets in individual women, although the 
study addressing this question is yet to be conducted.71
Pharmacotherapy
If women cannot achieve glycemic goals with the strate-
gies outlined above, pharmacotherapy with insulin is 
  recommended.7 The mainstay of pharmacotherapy during 
pregnancy has been neutral protamine Hagedorn insulin 
for basal injections 2–4 times daily. Continuous insulin 
infusion of a rapid-acting insulin analog, such as lispro 
and aspart, are sometimes used instead if patients are able 
to check their blood glucose levels and glucose monitor-
ing devices frequently.72 These analogs have not been well 
studied during GDM pregnancy, in that outcome data 
are not available,7 although analogs are associated with 
a decrease in hypoglycemic episodes and greater patient 
satisfaction.72
Insulin may be administered according to the woman’s 
pattern of glucose administration. If the fasting glucose is 
elevated in the morning, evening neutral protamine   Hagedorn 
insulin can be used, at a typical starting dose of 0.2 units/kg 
body weight. If postprandial glucoses are elevated, short-
acting insulins at doses of 1.5 units per 10 g per carbohydrate 
per breakfast and 1.0 units per 10 g per carbohydrate per 
lunch and dinner can be used. If both pre- and postprandial 
glucoses are elevated, four injections per day can be used at 
0.9–1.0 units/kg. Insulin can be divided into 50% neutral 
protamine Hagedorn insulin and 50% as three preprandial 
rapid-acting injections. These regimens are largely adapted 
from those used in women with preconception diabetes dur-
ing pregnancy.73
Theoretically, the use of oral agents is appealing, in 
that subcutaneous injections can be avoided, leading to 
  subsequent improvement in glucose levels, as well as patient 
satisfaction. While use in the community is common,74 oral 
sulfonylureas, particularly glyburide, have not yet been 
endorsed by the ADA or the ACOG, due to concerns about 
impact upon perinatal outcomes. The MiG trial found that 
46% of women randomized to metformin eventually required 
additional insulin, although the adverse outcome rate was 
not higher in the metformin group.5 In one trial of glyburide 
users versus insulin users, both groups attained similar rates 
of glycemic control.75 No differences in macrosomia and 
neonatal hypoglycemia were seen, but maternal and fetal 
outcomes were secondary outcomes and the study was not 
powered to detect differences.
Fetal monitoring
Although specific antepartum assessment techniques are 
not specifically endorsed by ACOG and other organizations, 
their use in clinical practice is routine. The most commonly 
used test is the twice-weekly nonstress test, which consists of 
continuous external fetal heart rate monitoring and evaluation 
of amniotic fluid volume.76 If the results of such testing are 
not reassuring, more specific testing, such as the biophysical 
profile,77 contraction stress test,78 or umbilical artery Doppler 
evaluations79 can help determine if fetal hypoxia is present. 
There is a wide range of practice due to lack of evidence for 
specific strategies and the timing of such strategies.80 In GDM 
pregnancies that are managed without pharmacotherapy 
and are normoglycemic, such testing commonly begins at 
approximately 37 weeks, and in more complicated GDM 
pregnancies, testing commonly begins at approximately International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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32 weeks. Intervention in the form of induction can then 
occur if indicated.30 As noted earlier, the evidence base will 
probably always be somewhat limited by the low rate of 
stillbirth and the unlikeliness of a randomized trial to test 
such strategies.
Fetal ultrasonography is generally performed for assess-
ment of fetal growth, as well as for detection of anomalies. The 
first ultrasound usually occurs at diagnosis of GDM.1 Thereaf-
ter, it may occur as often as every three weeks, particularly in 
the presence of comorbidities that can also affect fetal growth 
such as hypertension, but the timing and frequency are con-
troversial. Maternal obesity limits the accuracy of such testing 
for anomaly detection; in one study, at 25 weeks’ gestation, 
women with BMIs in the 90th percentile had visualization of 
fetal structures decreased by about a tenth to a third.81 Visu-
alization may be improved with transumbilical approaches 
or in the second trimester in obese women.82 However, even 
with these limitations, the use of ultrasound can decrease the 
rate of shoulder dystocia by leading to induction of labor for 
fetal growth above the 90th percentile at 38 weeks or for fetal 
weights estimated at or above 4250 g.83
Women with GDM may also engage in “daily kick 
counts” during the last 10 weeks of pregnancy, with more 
intensive medical evaluation applied in the case of reduction 
in fetal movement.84 The value of this strategy as a substitute 
for the more intensive monitoring outlined in the previous 
paragraph is unknown, and both maternal self-monitoring, as 
well as a nonstress test, are generally both performed.84
Labor management
There is no consensus on the timing of induction of labor 
in women with GDM, with its mixture of risks and benefits. 
Risks include cesarean section with its attendant complica-
tions, and benefits include decreased fetal growth, dystocia, 
and stillbirth.30 Currently, women with GDM are monitored 
closely for excess fetal growth, and induction is usually 
recommended when women exceed those parameters, with 
fairly low thresholds to induce or after 40 weeks.
During induced and spontaneous labor, insulin require-
ments generally increase due to the work of the uterus. How-
ever, women may still require continuous insulin, particularly 
if they required pharmacotherapy during the pregnancy. In 
these women, glucose is monitored continuously or at least 
every two hours, and insulin infusions are started when 
the woman is mildly hyperglycemic at 120 mg/dL. Insulin 
infusions are preferred to subcutaneous injections due to 
women’s rapidly changing caloric needs during labor and 
unpredictable oral intake. Conversely, dextrose infusions are 
given when women’s glucose levels drop below 60 mg/dL 
or when they experience symptoms of hypoglycemia. As with 
insulin use during pregnancy, insulin and glucose manage-
ment during labor are based primarily on trials of women 
with preconception diabetes.85
Postpartum management 
and treatment options
Postpartum screening for diabetes
Because up to 10% of GDM cases actually represent 
undiagnosed diabetes, postpartum glucose testing can 
confirm continuing glucose intolerance.86 Therefore, sev-
eral organizations endorse some type of glucose screening 
at the postpartum visit.1,7,87 As with the tests used for the 
index GDM diagnosis, there is not complete consensus on 
the optimal test. Fasting glucose and postprandial glucose 
levels will detect glucose intolerance in different popula-
tions, and only about one-third of the glucose-intolerant 
population will have defects in both compared with one 
or the other test.88,89 However, the impact of performing a 
2-hour 75 g OGTT as opposed to a single fasting glucose 
upon maternal outcomes and outcomes of future pregnan-
cies has not been examined. Similarly, the hemoglobin A1c 
assay will detect an overlapping but not identical popula-
tion of glucose-intolerant women,90 but it is unknown if the 
women diagnosed as glucose-tolerant by the hemoglobin 
A1c and intolerant by the 2-hour glucose value will suffer 
from misclassification. At the time of this review, the ADA 
has endorsed the use of the hemoglobin A1c as a diabetes 
screen,89 and no studies have examined its diagnostic 
properties compared with other glucose screens in the 
postpartum GDM population.
Contraception and breastfeeding
Breastfeeding encourages weight loss and, apart from weight, 
is associated with better glucose tolerance and reduced inci-
dence of future metabolic syndrome.91,92 A review of all the 
potential benefits of breastfeeding are beyond the scope of 
this article, and the reader is referred to Gunderson’s review.93 
Breastfeeding is associated with a lower risk of overweight 
and obesity during childhood and adolescence in the general 
population, but whether breastfeeding has the same protec-
tive effects among women with GDM has not been stud-
ied.94 Due to the other benefits of breastfeeding (upon other 
offspring outcomes aside from weight and glucose) and the 
absence of risk associated with breastfeeding, breastfeeding 
is generally encouraged for women with histories of glucose 
intolerance.94International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Breastfeeding without supplementation will lead to 
lactational amenorrhea, a highly effective contraceptive 
strategy in the first six months postpartum.95 Women must be 
exclusively breastfeeding in order to prevent ovulation, and 
because return to fertility may precede menstruation, backup 
barrier methods are encouraged.96 Estrogen-progestin based 
methods, including most birth control pills, as well as the 
ethinyl estradiol-etonorgestrel ring and patch, do not appear 
to affect glucose levels adversely and are highly effective.96,97 
Intrauterine devices are the most commonly used effective 
contraception outside of the US, and the levonorgestrel form 
has not been demonstrated to have adverse effects upon 
glucose among women with type 1 diabetes.98 This progestin 
intrauterine device leads to less menorrhagia than the cop-
per intrauterine device,98 and therefore may be preferred by 
women with heavy menses. Progestin-only strategies which 
significantly raise systemic progestin levels, either in pill 
or injection form, have been shown to increase the risk of 
glucose intolerance in specific populations and are therefore 
not first-line choices.97
Lifestyle modification
The majority of women with histories of GDM are over-
weight or obese, have sedentary lifestyles, and consume 
few vegetables and fruits.99 In contrast, weight targets 
of ,25 kg/m2, physical activity of $2.5 hours/week of 
moderate aerobic activity or 75 minutes/week of vigorous-
intensity aerobic activity or an equivalent,100 and consumption 
of five or more servings of fruits and vegetables per day, are 
recommended.99
In the Diabetes Prevention Program, women with GDM 
approximately a decade after their last pregnancy were able 
to decrease their diabetes risk with a goal of weight reduction 
of 7% of their baseline weight.101 In turn, this weight loss was 
achieved through increased physical activity and attention to 
caloric reduction and calorie quality.
Similarly, in the immediate postpartum period, caloric 
reduction and weight loss can be achieved. However, evidence 
from randomized trials is lacking for GDM women. Among 
overweight and obese women, randomization to a 12-week 
postpartum exercise program was not associated with sig-
nificant weight loss.102 In contrast, a combination of both diet 
and physical activity was associated with weight loss in other 
randomized studies, suggesting that both caloric restriction, as 
well as physical activity, are needed to reduce weight.103,104
The high attrition levels in these studies underline the 
difficulty of engaging in any intervention in the postpartum 
period. This difficulty may extend for as long as a decade; 
in the Diabetes Prevention Program, attrition was low, but 
adherence to lifestyle intervention was lower at younger 
ages.101 Women with histories of GDM had less success with 
lifestyle intervention than women without histories of GDM, 
although they differed only in age, ie, 43 years in the GDM 
women compared with 51 years in the women without GDM. 
Women with and without GDM who were randomized to 
lifestyle changes both increased activity in the first year of 
the intervention, but this improvement was not sustained in 
the GDM women; similarly, the weight loss achieved in the 
first year was less sustained in the GDM women than in the 
women without GDM. It is possible that the younger age of 
the GDM population was associated with younger children 
and the greater caregiving demands associated with younger 
children, thus leading to decreased adherence, but this infor-
mation was not collected as part of the trial.
Currently, medications are not recommended for the 
prevention of diabetes among women with recent GDM. 
The Troglitazone in Prevention of Diabetes Study found that 
randomization to a thiazolidinedione was associated with a 
decreased risk of diabetes among women with recent GDM,105 
but the trial was discontinued due to the side effects of tro-
glitazone, and the drug was subsequently withdrawn from 
the market. Metformin may offer a reasonable alternative for 
women with histories of GDM who have impaired glucose 
tolerance and who are overweight. Currently, no organizations 
endorse it for this purpose among women with recent GDM, 
who are usually in their fourth decade of life and might require 
use of the drug for decades. Moreover, women with GDM 
are, by definition, of child-bearing age, and metformin could 
potentially impact outcomes in future pregnancies.
Conclusions
If recent recommendations for diagnosis are adopted, GDM 
is poised to become one of the most common comorbidities 
of pregnancy. Even if current diagnostic criteria remain 
unchanged, the prevalence of GDM will continue to 
increase as obesity rates rise. While broad consensus exists 
on the association between glucose levels and adverse peri-
natal and postpartum outcomes in the mother and offspring, 
there is disagreement between medical organizations on 
strategies for monitoring and treatment. Close attention 
to fetal growth and stress in conjunction with maternal 
glucose and weight monitoring during pregnancy, followed 
by delivery if targets are exceeded, appear to minimize 
adverse outcomes.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Further studies in the prenatal period are needed to 
establish the optimal glucose and weight targets to minimize 
adverse outcomes, and the timing and dose of pharmaco-
therapy. Further studies in the postpartum period are also 
needed to establish the intervals and assays for postpartum 
screening and the effectiveness of interventions for diabetes 
prevention in the mother and offspring. Such attention could 
potentially offset the significant morbidity associated with 
chronic diabetes by leveraging the greater contact women 
have with medical care during pregnancy.
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